Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS).

Trial Profile

Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2011

At a glance

  • Drugs Ezatiostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Telik
  • Most Recent Events

    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Telik media release.
    • 29 Sep 2011 Results publised online in Cancer.
    • 01 Sep 2011 Results published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top